AustralieFrV1, PascalFrancis, Corpus, bibRecord, 000503

Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data

Identifieur interne : 000503 ( PascalFrancis/Corpus ); précédent : 000502; suivant : 000504

Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data

Auteurs : Kevin Damman ; W. H. Wilson Tang ; G. Michael Felker ; Johan Lassus ; Faiez Zannad ; Henry Krum ; John J. V. Mcmurray

Source :

Journal of the American College of Cardiology [ 0735-1097 ] ; 2014.

RBID : Pascal:14-0088162

Descripteurs français

Pascal (Inist)
- Insuffisance cardiaque, Pathologie de l'appareil circulatoire, Traitement, Homme, Malade, Donnée, Appareil circulatoire, Cardiologie, Insuffisance rénale chronique.

English descriptors

KwdEn :
- Cardiology, Cardiovascular disease, Chronic renal failure, Circulatory system, Data, Heart failure, Human, Patient, Treatment.

Abstract

Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0735-1097`
A02	`01`			`@0 JACCDI`
A03		`1`		`@0 J. Am. Coll. Cardiol.`
A05				`@2 63`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data`
A11	`01`	`1`		`@1 DAMMAN (Kevin)`
A11	`02`	`1`		`@1 TANG (W. H. Wilson)`
A11	`03`	`1`		`@1 FELKER (G. Michael)`
A11	`04`	`1`		`@1 LASSUS (Johan)`
A11	`05`	`1`		`@1 ZANNAD (Faiez)`
A11	`06`	`1`		`@1 KRUM (Henry)`
A11	`07`	`1`		`@1 McMURRAY (John J. V.)`
A14	`01`			`@1 British Heart Foundation Cardiovascular Research Centre, University of Glasgow @2 Glasgow, Scotland @3 GBR @Z 1 aut. @Z 7 aut.`
A14	`02`			`@1 University of Groningen, Department of Cardiology, University Medical Center Groningen @2 Groningen @3 NLD @Z 1 aut.`
A14	`03`			`@1 Heart and Vascular Institute, Cleveland Clinic @2 Cleveland, Ohio @3 USA @Z 2 aut.`
A14	`04`			`@1 Duke Clinical Research Institute @2 Durham, North Carolina @3 USA @Z 3 aut.`
A14	`05`			`@1 Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital @2 Helsinki @3 FIN @Z 4 aut.`
A14	`06`			`@1 INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University @2 Nancy @3 FRA @Z 5 aut.`
A14	`07`			`@1 Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University @2 Melbourne, Victoria @3 AUS @Z 6 aut.`
A20				`@1 853-871`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20098 @5 354000506158800010`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 81 ref.`
A47	`01`	`1`		`@0 14-0088162`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of the American College of Cardiology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.
C02	`01`	`X`		`@0 002B12A01`
C02	`02`	`X`		`@0 002B14A05`
C03	`01`	`X`	`FRE`	`@0 Insuffisance cardiaque @5 01`
C03	`01`	`X`	`ENG`	`@0 Heart failure @5 01`
C03	`01`	`X`	`SPA`	`@0 Insuficiencia cardíaca @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 02`
C03	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 09`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 09`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 09`
C03	`04`	`X`	`FRE`	`@0 Homme @5 10`
C03	`04`	`X`	`ENG`	`@0 Human @5 10`
C03	`04`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`05`	`X`	`FRE`	`@0 Malade @5 11`
C03	`05`	`X`	`ENG`	`@0 Patient @5 11`
C03	`05`	`X`	`SPA`	`@0 Enfermo @5 11`
C03	`06`	`X`	`FRE`	`@0 Donnée @5 12`
C03	`06`	`X`	`ENG`	`@0 Data @5 12`
C03	`06`	`X`	`SPA`	`@0 Dato @5 12`
C03	`07`	`X`	`FRE`	`@0 Appareil circulatoire @5 13`
C03	`07`	`X`	`ENG`	`@0 Circulatory system @5 13`
C03	`07`	`X`	`SPA`	`@0 Aparato circulatorio @5 13`
C03	`08`	`X`	`FRE`	`@0 Cardiologie @5 14`
C03	`08`	`X`	`ENG`	`@0 Cardiology @5 14`
C03	`08`	`X`	`SPA`	`@0 Cardiología @5 14`
C03	`09`	`X`	`FRE`	`@0 Insuffisance rénale chronique @4 CD @5 96`
C03	`09`	`X`	`ENG`	`@0 Chronic renal failure @4 CD @5 96`
C03	`09`	`X`	`SPA`	`@0 Insuficiencia renal crónica @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Urinary system disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato urinario patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie du rein @5 38`
C07	`02`	`X`	`ENG`	`@0 Kidney disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Riñón patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Cardiopathie @5 39`
C07	`03`	`X`	`ENG`	`@0 Heart disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Cardiopatía @5 39`
N21				`@1 118`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0088162 INIST
ET :	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data
AU :	DAMMAN (Kevin); TANG (W. H. Wilson); FELKER (G. Michael); LASSUS (Johan); ZANNAD (Faiez); KRUM (Henry); McMURRAY (John J. V.)
AF :	British Heart Foundation Cardiovascular Research Centre, University of Glasgow/Glasgow, Scotland/Royaume-Uni (1 aut., 7 aut.); University of Groningen, Department of Cardiology, University Medical Center Groningen/Groningen/Pays-Bas (1 aut.); Heart and Vascular Institute, Cleveland Clinic/Cleveland, Ohio/Etats-Unis (2 aut.); Duke Clinical Research Institute/Durham, North Carolina/Etats-Unis (3 aut.); Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital/Helsinki/Finlande (4 aut.); INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University/Nancy/France (5 aut.); Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University/Melbourne, Victoria/Australie (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of the American College of Cardiology; ISSN 0735-1097; Coden JACCDI; Etats-Unis; Da. 2014; Vol. 63; No. 9; Pp. 853-871; Bibl. 81 ref.
LA :	Anglais
EA :	Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.
CC :	002B12A01; 002B14A05
FD :	Insuffisance cardiaque; Pathologie de l'appareil circulatoire; Traitement; Homme; Malade; Donnée; Appareil circulatoire; Cardiologie; Insuffisance rénale chronique
FG :	Pathologie de l'appareil urinaire; Pathologie du rein; Cardiopathie
ED :	Heart failure; Cardiovascular disease; Treatment; Human; Patient; Data; Circulatory system; Cardiology; Chronic renal failure
EG :	Urinary system disease; Kidney disease; Heart disease
SD :	Insuficiencia cardíaca; Aparato circulatorio patología; Tratamiento; Hombre; Enfermo; Dato; Aparato circulatorio; Cardiología; Insuficiencia renal crónica
LO :	INIST-20098.354000506158800010
ID :	14-0088162

Links to Exploration step

Pascal:14-0088162

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data</title>
<author><name sortKey="Damman, Kevin" sort="Damman, Kevin" uniqKey="Damman K" first="Kevin" last="Damman">Kevin Damman</name>
<affiliation><inist:fA14 i1="01"><s1>British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow, Scotland</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Groningen, Department of Cardiology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tang, W H Wilson" sort="Tang, W H Wilson" uniqKey="Tang W" first="W. H. Wilson" last="Tang">W. H. Wilson Tang</name>
<affiliation><inist:fA14 i1="03"><s1>Heart and Vascular Institute, Cleveland Clinic</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Felker, G Michael" sort="Felker, G Michael" uniqKey="Felker G" first="G. Michael" last="Felker">G. Michael Felker</name>
<affiliation><inist:fA14 i1="04"><s1>Duke Clinical Research Institute</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lassus, Johan" sort="Lassus, Johan" uniqKey="Lassus J" first="Johan" last="Lassus">Johan Lassus</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation><inist:fA14 i1="06"><s1>INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation><inist:fA14 i1="01"><s1>British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow, Scotland</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0088162</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0088162 INIST</idno>
<idno type="RBID">Pascal:14-0088162</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000503</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data</title>
<author><name sortKey="Damman, Kevin" sort="Damman, Kevin" uniqKey="Damman K" first="Kevin" last="Damman">Kevin Damman</name>
<affiliation><inist:fA14 i1="01"><s1>British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow, Scotland</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Groningen, Department of Cardiology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tang, W H Wilson" sort="Tang, W H Wilson" uniqKey="Tang W" first="W. H. Wilson" last="Tang">W. H. Wilson Tang</name>
<affiliation><inist:fA14 i1="03"><s1>Heart and Vascular Institute, Cleveland Clinic</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Felker, G Michael" sort="Felker, G Michael" uniqKey="Felker G" first="G. Michael" last="Felker">G. Michael Felker</name>
<affiliation><inist:fA14 i1="04"><s1>Duke Clinical Research Institute</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lassus, Johan" sort="Lassus, Johan" uniqKey="Lassus J" first="Johan" last="Lassus">Johan Lassus</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zannad, Faiez" sort="Zannad, Faiez" uniqKey="Zannad F" first="Faiez" last="Zannad">Faiez Zannad</name>
<affiliation><inist:fA14 i1="06"><s1>INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name>
<affiliation><inist:fA14 i1="01"><s1>British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow, Scotland</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American College of Cardiology</title>
<title level="j" type="abbreviated">J. Am. Coll. Cardiol.</title>
<idno type="ISSN">0735-1097</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiology</term>
<term>Cardiovascular disease</term>
<term>Chronic renal failure</term>
<term>Circulatory system</term>
<term>Data</term>
<term>Heart failure</term>
<term>Human</term>
<term>Patient</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuffisance cardiaque</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Traitement</term>
<term>Homme</term>
<term>Malade</term>
<term>Donnée</term>
<term>Appareil circulatoire</term>
<term>Cardiologie</term>
<term>Insuffisance rénale chronique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0735-1097</s0>
</fA01>
<fA02 i1="01"><s0>JACCDI</s0>
</fA02>
<fA03 i2="1"><s0>J. Am. Coll. Cardiol.</s0>
</fA03>
<fA05><s2>63</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DAMMAN (Kevin)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TANG (W. H. Wilson)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FELKER (G. Michael)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LASSUS (Johan)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ZANNAD (Faiez)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KRUM (Henry)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>McMURRAY (John J. V.)</s1>
</fA11>
<fA14 i1="01"><s1>British Heart Foundation Cardiovascular Research Centre, University of Glasgow</s1>
<s2>Glasgow, Scotland</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Groningen, Department of Cardiology, University Medical Center Groningen</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Heart and Vascular Institute, Cleveland Clinic</s1>
<s2>Cleveland, Ohio</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Duke Clinical Research Institute</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>853-871</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20098</s2>
<s5>354000506158800010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>81 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0088162</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the American College of Cardiology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B12A01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B14A05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Insuffisance cardiaque</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Heart failure</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Insuficiencia cardíaca</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Malade</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Patient</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Enfermo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Donnée</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Data</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Dato</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Appareil circulatoire</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Circulatory system</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Aparato circulatorio</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cardiologie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cardiology</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cardiología</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Insuffisance rénale chronique</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Chronic renal failure</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Insuficiencia renal crónica</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie du rein</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Kidney disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Riñón patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cardiopathie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Heart disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cardiopatía</s0>
<s5>39</s5>
</fC07>
<fN21><s1>118</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0088162 INIST</NO>
<ET>Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data</ET>
<AU>DAMMAN (Kevin); TANG (W. H. Wilson); FELKER (G. Michael); LASSUS (Johan); ZANNAD (Faiez); KRUM (Henry); McMURRAY (John J. V.)</AU>
<AF>British Heart Foundation Cardiovascular Research Centre, University of Glasgow/Glasgow, Scotland/Royaume-Uni (1 aut., 7 aut.); University of Groningen, Department of Cardiology, University Medical Center Groningen/Groningen/Pays-Bas (1 aut.); Heart and Vascular Institute, Cleveland Clinic/Cleveland, Ohio/Etats-Unis (2 aut.); Duke Clinical Research Institute/Durham, North Carolina/Etats-Unis (3 aut.); Department of Cardiology, Heart and Lung Center, Helsinki University Central Hospital/Helsinki/Finlande (4 aut.); INSERM, Centre d'Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University/Nancy/France (5 aut.); Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University/Melbourne, Victoria/Australie (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of the American College of Cardiology; ISSN 0735-1097; Coden JACCDI; Etats-Unis; Da. 2014; Vol. 63; No. 9; Pp. 853-871; Bibl. 81 ref.</SO>
<LA>Anglais</LA>
<EA>Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available.</EA>
<CC>002B12A01; 002B14A05</CC>
<FD>Insuffisance cardiaque; Pathologie de l'appareil circulatoire; Traitement; Homme; Malade; Donnée; Appareil circulatoire; Cardiologie; Insuffisance rénale chronique</FD>
<FG>Pathologie de l'appareil urinaire; Pathologie du rein; Cardiopathie</FG>
<ED>Heart failure; Cardiovascular disease; Treatment; Human; Patient; Data; Circulatory system; Cardiology; Chronic renal failure</ED>
<EG>Urinary system disease; Kidney disease; Heart disease</EG>
<SD>Insuficiencia cardíaca; Aparato circulatorio patología; Tratamiento; Hombre; Enfermo; Dato; Aparato circulatorio; Cardiología; Insuficiencia renal crónica</SD>
<LO>INIST-20098.354000506158800010</LO>
<ID>14-0088162</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000503 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000503 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0088162
   |texte=   Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data

Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri